For someone experiencing memory problems, waiting for answers can be one of the most difficult parts of seeking care. Diagnosing Alzheimer’s disease isn’t always straightforward. Memory changes can have many causes, and patients may undergo multiple appointments, cognitive assessments, brain scans, or other specialized testing before doctors can confidently identify what’s happening. But what if a blood test could help shorten that uncertainty?
A randomized clinical trial published October 5, 2026, in JAMA Neurology offers encouraging evidence. Researchers found that sharing Alzheimer’s-related blood test results earlier helped neurologists reach more confident diagnoses and make treatment decisions sooner. The findings arrive as blood-based Alzheimer’s testing is beginning to move into clinical practice.
What Can an Alzheimer’s Blood Test Reveal?
Alzheimer’s disease is associated with changes in the brain, including the accumulation of amyloid plaques and abnormal tau proteins. Researchers have developed blood tests that look for biological signals associated with these changes. One promising marker is phosphorylated tau 217, or p-tau217, which is associated with Alzheimer’s-related brain pathology. Another, neurofilament light chain (NfL), can indicate nerve-cell damage, although it is not specific to Alzheimer’s disease.
These tests are not standalone diagnoses. Doctors must interpret the results alongside symptoms, cognitive assessments, and other clinical information. Importantly, not every result provides a clear answer. Very high or very low p-tau217 levels can be particularly informative, while intermediate results may leave considerable uncertainty.
What Happened When Patients Received Results Earlier?
Researchers in Spain studied 220 people being evaluated for cognitive symptoms at a memory clinic. Participants included people with mild dementia (23.6%), mild cognitive impairment (30.9%), and subjective cognitive decline (45.5%), meaning they reported cognitive changes without necessarily showing measurable impairment on testing. Participants and their treating neurologists received blood biomarker results either three months or nine months after their initial evaluation.
At three months, the difference was striking. Among patients who received their results earlier, 50% had an underlying diagnosis their neurologist considered at least 90% certain. Among those still waiting for results, only 4.6% reached that level of diagnostic certainty. Earlier disclosure also influenced care decisions. Symptomatic Alzheimer’s medications were initiated in 14.3% of patients in the early-results group, compared with 4.6% in the delayed group. These are treatments such as cholinesterase inhibitors, which help manage symptoms. The trial did not report initiation of anti-amyloid therapies.
Doctors also planned fewer repeat cognitive assessments and more discharges back to primary care. Importantly, sharing results earlier with patients was not associated with increased anxiety, depression, or perceived stress. However, the advantage was primarily about timing. Once the delayed group received its results at nine months, diagnostic confidence became similar between groups overall. Patients with mild cognitive impairment were an exception, with higher certainty persisting in the early-disclosure group.
Why This Matters for Alzheimer’s Care
The study represents an important step in understanding how blood biomarkers might influence clinical practice, but there are limitations. Nearly half of participants had subjective cognitive decline, a population in which positive blood biomarker results can be more difficult to interpret because the likelihood of underlying Alzheimer’s pathology may be lower. Current Alzheimer’s Association clinical guidance focuses on testing people with objectively confirmed cognitive impairment. The trial also took place at a single memory clinic and measured changes in clinical decisions, not whether earlier testing improved memory, slowed disease progression, or reduced hospitalizations.
Still, the regulatory landscape is moving quickly. The FDA cleared its first Alzheimer’s blood test in May 2025, and additional tests have since received authorization. These tests are intended to help evaluate people with cognitive symptoms, not to screen people without symptoms or monitor responses to anti-amyloid treatment. As the technology advances, blood testing could eventually make parts of Alzheimer’s evaluation more accessible, particularly for patients who face barriers to advanced imaging or spinal fluid testing.
What Pharmacists Should Be Watching
As Alzheimer’s blood testing becomes more common, pharmacists may increasingly encounter patients whose diagnoses and treatment plans are influenced by biomarker results. Understanding what these tests measure, their limitations, and how they fit into the diagnostic process will become increasingly valuable when supporting patients and caregivers. A positive biomarker result does not automatically establish eligibility for anti-amyloid medications, which require additional clinical evaluation and confirmation according to the specific therapy’s requirements. Pharmacists can also help patients understand the difference between symptomatic medications, such as donepezil and rivastigmine, and disease-modifying anti-amyloid therapies.
For years, the biggest question surrounding Alzheimer’s blood tests was whether they could accurately detect disease-related changes. Now researchers are asking something more practical: What happens when patients and doctors receive that information earlier? This new trial suggests they can reach important decisions months sooner. Whether those earlier decisions ultimately improve long-term patient outcomes remains an important question for future research.
Resources
Estragués-Gázquez I, Contador J, Martínez LD, et al. Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A
Randomized Clinical Trial. JAMA Neurology. Published October 5, 2026. doi:10.1001/jamaneurol.2026.3497. Read the study.
Alzheimer’s Association. Clinical Practice Guideline on the Use of Blood-Based Biomarkers in the Diagnostic Workup of Alzheimer’s Disease Within Specialized Care Settings. Alzheimer’s & Dementia. 2025. Alzheimer’s Association.
U.S. Food and Drug Administration. FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. May 16, 2025. FDA announcement.
U.S. Food and Drug Administration. Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio. FDA 510(k) Clearance K242706. FDA clearance record.
U.S. Food and Drug Administration. Elecsys Phospho-Tau (217P) Plasma. FDA 510(k) Clearance K261686. FDA clearance record.
